Yes, melanoma is always malignant. The word “melanoma” itself refers to a cancer of melanocytes, the pigment-producing cells in your skin. If a growth made of melanocytes is not malignant, it gets a different name: a mole (nevus), a melanocytoma, or another term that signals it hasn’t crossed the line into cancer. So if a doctor uses the word “melanoma” in your diagnosis, it means the lesion is cancerous by definition.
Why the Term Itself Means Cancer
The National Library of Medicine defines melanoma as “a malignancy derived from the malignant transformation of melanocytes.” There is no such thing as a “benign melanoma” in modern medical classification. The World Health Organization’s 5th Edition classification of skin tumors organizes melanocytic growths on a spectrum from benign to malignant: moles (nevi) sit at the benign end, melanocytomas occupy an intermediate zone, and melanoma sits at the malignant end. Each term marks a distinct step in that progression.
This matters because people sometimes hear “melanoma” and wonder whether their specific case might be one of the harmless ones. It won’t be. If a pathologist examines your tissue and determines it doesn’t meet the criteria for malignancy, they won’t call it melanoma. They’ll call it something else.
What Sits Between a Mole and Melanoma
The confusion often comes from the fact that melanocytic growths exist on a biological spectrum, and the boundaries aren’t always razor-sharp under a microscope. A normal mole is a benign cluster of melanocytes. An atypical mole (dysplastic nevus) looks unusual but is still not cancerous. Then there are melanocytomas, a category the WHO recently expanded to describe growths that have progressed one step beyond a conventional mole but haven’t acquired enough abnormal features to qualify as melanoma.
Spitz tumors are a particularly tricky example. A Spitz nevus is a benign growth that most often appears in children and young adults. A Spitz melanocytoma (sometimes called an atypical Spitz tumor) is an intermediate lesion. And a Spitz melanoma is a true cancer. All three can look strikingly similar under a microscope, which is why pathologists sometimes struggle to classify them. Distinguishing features include asymmetry, sheet-like growth patterns, failure of cells to mature as they go deeper into the skin, and the presence of cells actively dividing in the deeper layers of the tissue. But the key point is that only the one called “melanoma” is malignant.
How Pathologists Decide It’s Melanoma
When a suspicious mole is removed and sent to a lab, a pathologist examines it under a microscope looking for a specific set of features. At the architectural level, they check whether the lesion is asymmetrical, poorly defined at its edges, and larger than 6 mm. They look at whether individual abnormal melanocytes outnumber organized clusters (nests) of cells, and whether melanocytes have spread upward into layers of skin where they don’t belong.
At the cellular level, the signs of malignancy include cells with enlarged, irregularly shaped nuclei, cells caught in the act of dividing (especially deep in the skin), and dead melanocytes within the tissue. One important marker is whether the cells “mature” as they go deeper into the skin. In a benign mole, melanocytes get smaller and more orderly the deeper they sit. In melanoma, they don’t.
To confirm that the abnormal cells are actually melanocytes and not some other type of cancer cell, pathologists use special staining techniques. Proteins called S100, SOX10, and Melan-A are present in melanocytes, and staining positive for these markers helps confirm the diagnosis. These stains are consistent across the vast majority of melanoma cases.
Not All Melanomas Are Equally Dangerous
While every melanoma is malignant, the word “malignant” covers an enormous range of severity. The single biggest factor in how dangerous a melanoma is: how deep it has grown into the skin, measured in millimeters (called Breslow depth).
A melanoma thinner than 0.8 mm has less than a 1% chance of having spread to nearby lymph nodes. Between 0.8 and 1.5 mm, that risk climbs to about 8%. Between 1.5 and 4.0 mm, it reaches roughly 23%. Above 4.0 mm, the risk is around 36%. Whether the surface of the melanoma is ulcerated (broken open) also matters, independently raising the risk of spread.
This is why survival rates vary so dramatically by stage. According to the American Cancer Society, based on data from 2015 to 2021, localized melanoma (still confined to the skin) has a five-year relative survival rate above 99%. Melanoma that has spread to distant parts of the body drops to 35%. The cancer is always malignant, but catching it early makes an extraordinary difference in outcome.
Melanoma in Situ: Malignant but Not Invasive
Stage 0 melanoma, called melanoma in situ, is sometimes the source of confusion. “In situ” means the cancerous melanocytes are confined entirely to the outermost layer of skin (the epidermis) and haven’t broken through into deeper tissue. It’s still classified as malignant because the cells themselves have undergone cancerous transformation. But because those cells haven’t invaded surrounding tissue, the risk of spread is essentially zero if the lesion is completely removed.
Think of it this way: the cells are cancerous, but they haven’t yet gained the ability to travel. This is why melanoma in situ is treated with surgery alone and carries an excellent prognosis. It’s also why your doctor will still use the word “melanoma” for it, because the cellular changes are real, and without removal, the lesion can progress to invasive melanoma over time.